Gabriel Tremblay Health Economist

Mister Tremblay and his partnerteam offer a broad range of Health Economics and Economic Evaluation services to the pharmaceutical industry Biotech companies Research centers private or public payers and governments Mister Tremblay is Based in the US and in Canada and offers countrywide services Health Economics Services Health Economics for Submissions for drugs and devices US payers CADTH NICE EU5 Socioeconomic proofofconcept for health genetics drugs or personalized medicine projects Advanced modeling disease modeling advanced markov model microsimulation Health Economics for Oncology Ophan drugs public health economics Personalized medicine and genetic project health economics Development of QALY HE using patient reported outcomes PRO My priorities as a consultant in health economics 1 Customer service I strive to always be available when my clients need me with quick turnaround for urgent projects 2 Valuable health economic analysis I am transparent when communicating potential limitations of an analysis and provide exceptional value to my clients The highest quality standards are applied to all my work whether oneday projects or longterm studies 3 Robust and

Gabriel Tremblay Health Economist provides professional consulting in Health Economics and economic evaluation for organizations across the pharmaceutical and biotech ecosystem, including research centers, private and public payers, and governments. Based in the US and in Canada, the practice supports clients with countrywide services, helping teams build credible evidence that demonstrates the value of treatments and health initiatives to healthcare systems, patients, and payers—relevant to decision-making environments in and around Boston, Massachusetts. Services include health economics for drug and device submissions, with experience supporting U.S. payers and recognized health technology assessment frameworks such as CADTH, NICE, and EU5. The firm also supports socioeconomic proof-of-concept work for health genetics and personalized medicine projects, along with advanced modeling approaches such as disease modeling, advanced Markov models, and microsimulation. Additional focus areas include health economics for oncology and orphan drugs, public health economics, and personalized medicine and genetic project health economics, including development of QALY estimates using patient-reported outcomes (PRO). Built around clear consulting priorities—responsive customer service with quick turnaround for urgent projects, transparent communication about potential analysis limitations, robust and well-communicated evidence, and strong teamwork with client teams and collaborators—Gabriel Tremblay Health Economist delivers high-quality health economic analysis for both short-term and long-term studies.